Posted by Michael Wonder on 22 Sep 2020
Medeor Therapeutics’ transplant immune tolerance therapy receives regenerative medicine advanced therapy designation from FDA
22 September 2020 - Medeor Therapeutics today announced that the U.S. FDA has granted a regenerative medicine advanced therapy designation to MDR-101, Medeor’s therapy designed to enable immune tolerance in kidney transplant patients, thereby eliminating the need for chronic immunosuppressive therapies.
MDR-101 is being developed to avert transplant kidney rejection by the recipient’s immune system without the need for chronic use of immunosuppressive drugs.
